Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Development of Light-Responsive Artificial Cells using Plant-Based Photoreceptor Systems

Awarded

W9132T269A011Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Department of Defense, through the W2R2 Construction Engineering Labor office, has issued award notice W9132T269A011 for the development of light-responsive artificial cells utilizing plant-based photoreceptor systems. This scientific endeavor falls under NAICS code 541714 and is focused on advancing synthetic biology and photoreceptor research. The project is managed by contracting officer Andrea Thomas and is designated for performance in Austin, Texas. There were no set-asides applied to this award, and the primary administrative coordination is handled through the USACE Army email system.

General Info

DoD award W9132T269A011 for light-responsive artificial cell research in Austin, Texas.

Agency

Department Of Defense → W2R2 Construction Engrg Labor

Contract Value

$156,000

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Austin, TX, 78748, USA

Set-Aside

NONE

Awardee

BIOCONSCIENTIA LLC

Award Issued Date

09/23/2026, 12:00:00 AM UTC

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded

PostedSep 23

Award Notice

AwardedSep 23

Contract was awarded

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Defense → W2R2 Construction Engrg Labor

Contacts1 person available

OfficeCHAMPAIGN, IL, 61822-1072, USA

Organization / AgencyDepartment Of Defense → W2R2 Construction Engrg Labor

Office AddressCHAMPAIGN, IL, 61822-1072, USA

Contacts

Andrea Thomas - Contracting Officer

contact@example.gov

Full Description

Show more

https://api.sam.gov/prod/opportunities/v1/noticedesc?noticeid=5dcbd08e6c30460f85b484ee9b86dbe1

Similar Contracts

Same NAICS industry code

Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories

Solicitation # 75N98026R00175SB

The National Institutes of Health is issuing a Small Business Sources Sought Notice to identify qualified small businesses capable of providing biobanking, laboratory analytics, and informatics services for NIH biorepositories starting in fiscal year 2028. The scope of work includes the management and secure storage of at least 3.5 million biospecimens, data curation and harmonization, and advanced laboratory capabilities such as high-throughput sequencing and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support to develop and maintain web portals, APIs, and secure cyberinfrastructure compliant with FISMA and NIH requirements. This notice is for market research purposes to determine the availability of small businesses under NAICS code 541714 and does not constitute a solicitation for proposals. Interested firms must submit a detailed capability statement by October 20, 2026, outlining their previous experience, personnel qualifications, and facility capabilities. The government is specifically looking for firms that can maintain a strict chain of custody, adhere to Good Laboratory Practice, and collaborate with NIH Data Centers to support large-scale research studies.

National Institutes Of Health Nida

POSTED

DEADLINE

Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories

Solicitation # 75N98026R00175

The National Institutes of Health is issuing a Sources Sought Notice to identify qualified research and development firms, small businesses, and subcontractors capable of providing biobanking, laboratory analytics, and informatics services for NIH biorepositories starting in fiscal year 2028. The primary objective is to support the operation and potential consolidation of repositories, specifically including the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank. This is a market research effort to determine the availability of technically capable sources and to inform the government's decision on the appropriate acquisition method and potential small business set-asides. The required scope of work involves the secure storage and tracking of at least 3.5 million biospecimens, comprehensive data curation and management using auditable LIMS, and advanced laboratory capabilities such as high-throughput sequencing and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support to develop and maintain web portals, APIs, and secure cyberinfrastructure compliant with FISMA standards. Interested parties must submit a detailed capability statement, including experience, personnel qualifications, and facility descriptions, to the designated contract specialists by October 20, 2026.

National Institutes Of Health Nida

POSTED

DEADLINE

Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)

Solicitation # ARPA-H-SOL-26-164

The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

in about 2 months

SURPASS Webinar and Proposers' Day Information

Solicitation # ARPA-H-SN-26-164

The Advanced Research Projects Agency for Health (ARPA-H), under the Department of Health and Human Services, has issued Special Notice ARPA-H-SN-26-164 regarding the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program. This initiative aims to modernize clinical research by transforming drug and biologics development into a continuous learning system, with the goal of reducing development timelines from over ten years to fewer than four. The program focuses on creating disease-specific multi-arm platforms that integrate AI-powered operational infrastructure, in silico modeling, and advanced adaptive designs to enable a seamless transition from first-in-patient evaluation to confirmatory assessment. Key outputs include a reusable blueprint for future trials, simulation-based design tools, and continuous inference and adaptation approaches, all aligning with the goals of HHS Operation TrialBlazer. This specific notice serves as an informational announcement and does not constitute a formal solicitation for proposals. It invites interested parties to an informational webinar on October 15, 2026, and a two-day Proposers Day on November 6 and 9, 2026. Potential participants may optionally submit teaming profiles, lightning talk slides, and posters to showcase their expertise. Full program details and formal solicitation requirements are located under solicitation ARPA-H-SOL-26-164. All inquiries are directed to the SURPASS team, with Daria Fedyukina serving as the Technical Point of Contact.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Neuroimaging Analysis and Data Collection

National Institutes Of Health

POSTED

DEADLINE

in about 1 year

ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening

Solicitation # ARPA-H-SOL-26-165

The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

ARPA-H Emerging Health Innovators (EHI) Initiative

Solicitation # ARPA-H-SOL-26-150

The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, is a mentorship program designed to identify and engage early-career investigators for cutting-edge biomedical, health, and community-engaged research. Eligible principal investigators must be within eight years of completing their first terminal degree. The program focuses on 16 specific topic areas and utilizes a two-step submission process, beginning with an anonymized solution summary due October 30, 2026, followed by full proposals due February 10, 2027. Awards are issued as Other Transaction (OT) agreements with a tentative start date of June 30, 2027. Each award has a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a two-year base period capped at 700,000 dollars and an optional third year capped at 350,000 dollars. Funding is structured around a fixed-price milestone payment schedule, with 12 total quarterly milestones and payments processed through the Payment Management Services (PMS) system. Performance is monitored via monthly one-hour virtual reviews with the ARPA-H program team. Evaluation is based on technical merit, innovativeness, feasibility, and alignment with the ARPA-H mission, with a strong emphasis on risk mitigation and the potential to impact national health research.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Imaging Biomarker Research & AnalysisThis subcontract focuses on the development and testing of imaging-based biomarkers designed to identify pancreatic cancer and its precursor lesions. Working in support of prime contractors on NIH and NCI research projects, the scope of work involves utilizing advanced imaging modalities including MRI, CT, PET, and endoscopic ultrasound to characterize lesions and establish specialized protocols for identifying high-risk patients. Because the work involves human subject research, all activities must be conducted under appropriate IRB approval. The primary deliverables for this engagement consist of finalized imaging biomarker protocols and comprehensive analyzed imaging datasets. This opportunity is categorized under NAICS code 541714 and is associated with the National Institutes of Health within the Department of Health and Human Services. Interested parties must note the response deadline of November 5, 2029, to participate in this research and analysis initiative.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Institutes of Health National Eye Institute is offering a bi-phasic, milestone-driven award through the Translational Research Program for Therapeutics (PAR-28-072) to accelerate the transition of laboratory research into biological, pharmaceutical, or medical device therapies for visual system diseases. The program is structured into two phases: an R61 phase of up to two years focusing on preliminary data and lead optimization, and an R33 phase of up to four years dedicated to final preclinical development and the filing of an Investigational New Drug or Investigational Device Exemption application with the FDA. The total combined duration of both phases cannot exceed five years. Transition to the R33 phase is contingent upon the administrative assessment of satisfactory completion of SMART milestones, which must include required pre-submission feedback from the FDA. Budgetary limits for direct costs are generally capped at 500,000 dollars per year for the R61 phase and 1,000,000 dollars per year for the R33 phase. Applicants must provide a Target Product Profile, a Gantt chart, and an Intellectual Property Strategy, while ensuring compliance with Good Manufacturing Practices and Good Laboratory Practice standards. Evaluation is based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Eligible applicants, including small businesses and other for-profit organizations, must maintain active registrations in the System for Award Management and eRA Commons, and all principal investigators must have a linked ORCID ID. Awardees are also required to implement cybersecurity incident reporting procedures and an incident response plan in accordance with HHS guidelines.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Institutes of Health, through the National Cancer Institute, is soliciting applications for Research Units (RUs) to join the Pancreatic Cancer Detection Consortium (PCDC). This initiative focuses on the early detection of pancreatic ductal adenocarcinoma (PDAC) and the characterization of precursor lesions to identify high-risk patients. Multi-disciplinary teams will conduct research to identify and test molecular and imaging biomarkers in bodily fluids, develop markers for pancreatic cysts, create screening approaches for high-risk populations, and utilize machine learning for biomarker discovery and validation. Additionally, RUs are required to collect longitudinal biospecimens for a biorepository and engage in collaborative data and resource sharing within the consortium. The award has a five-year project period with a budget limit of 600,000 dollars in direct costs per year. For years two through five, recipients must set aside 100,000 dollars in direct costs annually for trans-PCDC collaborative studies, subject to Steering Committee approval. Key personnel requirements include a minimum commitment of 1.2 person-months per year for the Contact PD/PI and any other PD/PIs. Eligible applicants include for-profit organizations and small businesses, though foreign entities are excluded. Applications are evaluated via the NIH peer review system based on significance, innovation, feasibility, and the expertise of the investigators and their environment. Compliance requirements include maintaining active SAM and eRA Commons registrations and adhering to strict cybersecurity incident reporting timelines of 48 hours. Projects involving clinical trials must be registered on ClinicalTrials.gov and receive NIH approval prior to initiation. Required application materials include SF424 forms, a Resource Sharing Plan, a Data Management and Sharing Plan, and letters of institutional commitment. Awardees must also budget for travel to attend two Steering Committee meetings annually.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Eye Institute's Translational Research Program (TRP) aims to accelerate the transition of laboratory research into clinical therapeutics for visual system diseases. This program supports the development of pharmaceutical, biological, medical device, or combination therapies through a bi-phasic, milestone-driven award structure. All projects begin with an R61 phase for up to two years to support research with significant preliminary data. Successful projects may transition to an R33 phase for up to four years, focusing on final preclinical development, filing IND/IDE packages with the FDA, and designing future clinical trials. The combined duration of both phases cannot exceed five years. A critical requirement of this program is the establishment of SMART milestones for both phases, which must be specific, measurable, achievable, relevant, and time-bound. Applicants are encouraged to provide contingency plans to address potential delays in meeting these goals. The ultimate objective of the R33 phase is for recipients to either obtain an IND/IDE application or transition the product into clinical practice within the performance period. This solicitation, identified as PAR-28-072, is issued by the National Institutes of Health.

National Eye Institute

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.

National Cancer Institute

POSTED

DEADLINE

in about 3 years

More opportunities from Department Of Defense → W2R2 Construction Engrg Labor

Same awarding agency

Bio-Based Insulating and Finishing SolutionsThis subcontract under the Department of Defense involves the supply and development of bio-based building insulation and finishing materials for prime contractors working on US Army Corps of Engineers projects. The scope focuses on creating commercial-off-the-shelf alternatives to synthetic products by utilizing bio-based polymers, organic insulating fibers, and bio-resins to provide insulating panels, finishes, and detailed material specifications. The project is categorized under NAICS code 238310 and is managed by W2R2 Construction Engrg Labor. The solicitation was posted on December 19, 2025, with a response deadline set for October 30, 2026.

Drywall and Insulation Contractors

POSTED

DEADLINE

Sustainable Structural Building SolutionsThis subcontract opportunity focuses on the supply and development of sustainable engineered wood, mass timber, and bio-structural building solutions for prime contractors working on US Army Corps of Engineers projects under the ERDC/CERL. The primary objective is to create and deliver structural systems using bio-based materials designed to replace traditional construction materials with commercialized mass timber solutions. The contract is managed by the Department of Defense through the W2R2 Construction Engrg Labor agency and falls under NAICS code 321219. Interested parties must respond by October 30, 2026, to provide validated structural systems or specific structural building components.

Reconstituted Wood Product Manufacturing

POSTED

DEADLINE

Unmanned/Robotic Engineering & Inspection SystemsThis subcontract for Unmanned/Robotic Engineering & Inspection Systems supports the Department of Defense through W2R2 Construction Engrg Labor on US Army Corps of Engineers projects. The scope involves the development and supply of robotic systems specialized for terrain shaping and non-destructive testing. The contractor is responsible for integrating autonomous controls into commercial off-the-shelf platforms to perform remote inspections of infrastructure across land, water, and confined spaces using underwater drones and field robotics. The primary deliverables include the robotic platforms themselves and detailed NDT inspection reports. Operating under NAICS code 541330, the contract was posted on December 19, 2025, with a response deadline of October 30, 2026.

Engineering Services

POSTED

DEADLINE

Additive Construction & 3D Printing TechnologyThis subcontract for Additive Construction and 3D Printing Technology supports US Army Corps of Engineers infrastructure projects through the provision of 3D printing hardware and additive construction materials. The scope involves deploying 3D printers for construction and developing autonomous material processing capabilities utilizing metals, concrete composites, and polymers. The contractor is responsible for delivering either the 3D printed structures themselves or the necessary printing hardware and autonomous delivery systems. Managed under the Department of Defense via W2R2 Construction Engrg Labor, the contract falls under NAICS code 333999. The solicitation was posted on December 19, 2025, with a response deadline set for October 30, 2026.

All Other Miscellaneous General Purpose Machinery Manufacturing

POSTED

DEADLINE

Energy and Water Efficiency & Security SystemsThis subcontract, titled Energy and Water Efficiency and Security Systems, involves the design and supply of innovative efficiency and security solutions for prime contractors working on US Army Corps of Engineers installation projects. The scope of work focuses on implementing water-saving technologies, energy-efficient power and HVAC systems, and security infrastructure through the use of energy recovery systems and smart water meters. The project is managed under the Department of Defense by W2R2 Construction Engrg Labor and falls under NAICS code 238220. The solicitation was posted on December 19, 2025, with a response deadline set for October 30, 2026. The primary objective is the delivery of fully installed efficiency systems and technical security solutions.

Plumbing, Heating, and Air-Conditioning Contractors

POSTED

DEADLINE

Engineer Research and Development Center (ERDC) - Construction Engineering Research Laboratory (CERL) Annual Commercial Solutions Opening (CSO)

Solicitation # W9132T26SC001

The Engineer Research and Development Center Construction Engineering Research Laboratory is issuing Commercial Solutions Opening W9132T26SC001 to acquire innovative commercial products, services, and technologies. This effort focuses on closing capability gaps and advancing technological capabilities across several broad areas of interest, including materials and structures, installation energy, warfighter engineering, operational energy, training lands and heritage, and sustainment management systems. The solicitation is open on a continuous basis through October 30, 2026, and targets solutions that improve efficiency, sustainability, and operational effectiveness in military and civilian environments. The acquisition follows a two-step process where the government first solicits solution briefs and subsequently issues a Request for Proposal if a solution is selected and funding is available. All resultant contracts will be firm-fixed price and are treated as commercial items under FAR part 12, with potential awards also falling under FAR parts 13, 15, or 35, or through prototype agreements. Evaluation is based on technical innovation, importance to agency programs, and the availability of funds. Interested parties must be registered in the System for Award Management to be eligible for award. Submissions must be made exclusively through the ERDCWERX platform and include a cover letter, a technical volume consisting of a solution brief and pitch deck, and a price volume. An optional five-minute video demonstration may also be provided. For solutions valued over 900,000 dollars, non-small business entities are required to submit a subcontracting plan.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS